First-in-human phase I study of the liposomal RNAi therapeutic Atu027 in patients with advanced cancer.

Beate Schultheis,Dirk Strumberg,Ansgar Santel,Frank Gebhardt,Michael Khan,Oliver Keil,Klaus Giese,Jörg Kaufmann

First-in-human phase I study of the liposomal RNAi therapeutic Atu027 in patients with advanced cancer.

2017

Beate Schultheis
Dirk Strumberg
Ansgar Santel
Frank Gebhardt
Michael Khan
Oliver Keil
Klaus Giese
Jörg Kaufmann

2508 Background: Atu027 is a novel vascular stabilising, anti-metastatic, RNAi therapeutic, targeting systemic endothelial cell function and the tumor vasculature. Atu027 comprises a liposomal part...

Keywords:

Cancer research
Pathology
Liposome
Endothelial stem cell
Cancer
Tumor vasculature
RNA interference
Medicine
in patient
first in human
advanced cancer
phase i study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations